Background Adjuvant treatment with mitotane is commonly used after resection of
adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of …

Although adrenocortical carcinoma (ACC) during pregnancy is rare, a retrospective review
of a case series at our hospital revealed that almost one third of our patients were women in …

Objective The management of adrenocortical carcinoma (ACC) recurrences remains
controversial, and we present herein our experience with postoperative ACC recurrences …

Обоснование. Адренокортикальный рак (АКР)–редкое заболевание,
характеризующееся агрессивным течением и быстрым метастазированием. Для …

Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options
and usually rapid tumor progression in case of metastatic disease. As further treatment …

Objective Mitotane is the standard therapy of adrenocortical carcinoma (ACC) due to its
relative selectivity of its cytotoxic effects toward adrenocortical cells. Therefore, it virtually …

Objective Primary adrenal malignant tumor is rare. The factors affecting the prognosis
remain poorly defined. This study targeted to construct and corroborate a model for …

Background: Mitotane is the only drug approved for the treatment of adrenocortical
carcinoma (ACC). Although it has been used for many years, its mechanism of action …

The prognostic stratification of the current AJCC/UICC TNM classification for adrenocortical
carcinoma (ACC) has been validated in only a few studies. In this study, it was hypothesized …

Background International guidelines emphasise the role of radiotherapy (RT) for the
management of advanced adrenocortical carcinoma (ACC). However, the evidence for this …